Creative Medical Technology Holdings (CELZ) Total Non-Current Liabilities (2015 - 2021)
Creative Medical Technology Holdings (CELZ) posted quarterly Total Non-Current Liabilities of $1.1 million for Q4 2021, down 40.95% year-over-year from $1.8 million in Q4 2020, and down 66.46% quarter-over-quarter from $3.1 million in Q3 2021.
Creative Medical Technology Holdings (CELZ) Total Non-Current Liabilities (2015 - 2021) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Total Non-Current Liabilities for 7 consecutive years, with $1.1 million the latest figure, recorded in Q4 2021.
- In Q4 2021, Total Non-Current Liabilities fell 40.95% year-over-year to $1.1 million; the TTM figure through Dec 2021 stood at $1.1 million (down 40.95% YoY), while the FY2021 annual figure was $1.1 million, down 40.95% from the prior year.
- Total Non-Current Liabilities slipped to $1.1 million in Q4 2021 per CELZ's latest filing, from $3.1 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $10.9 million in Q2 2018 and bottomed at -$1.4 million in Q1 2021.
- Historically, Total Non-Current Liabilities has averaged $2.9 million across 5 years, with a median of $2.4 million in 2017.
- Annual changes were most pronounced in 2018 — Total Non-Current Liabilities soared 1564.69% — and 2021, when it slumped 141.71%.
- Creative Medical Technology Holdings' Total Non-Current Liabilities stood at $2.4 million in 2017, then jumped by 83.56% to $4.5 million in 2018, then tumbled by 60.77% to $1.8 million in 2019, then gained by 1.4% to $1.8 million in 2020, then plunged by 40.95% to $1.1 million in 2021.
- Business Quant data shows CELZ's Total Non-Current Liabilities at $1.1 million in Q4 2021, $3.1 million in Q3 2021, and $484212.0 in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 9.32 Bn |
| 10 | Creative Medical Technology Holdings | 1.76 Mn | 1.76 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.05 Mn |
| Sep 30, 2021 | 3.13 Mn |
| Jun 30, 2021 | 484,212.00 |
| Mar 31, 2021 | -1.40 Mn |
| Dec 31, 2020 | 1.78 Mn |
| Sep 30, 2020 | 2.35 Mn |
| Jun 30, 2020 | 4.07 Mn |
| Mar 31, 2020 | 3.37 Mn |
| Dec 31, 2019 | 1.75 Mn |
| Sep 30, 2019 | 2.57 Mn |
| Jun 30, 2019 | 2.21 Mn |
| Mar 31, 2019 | 3.52 Mn |
| Dec 31, 2018 | 4.47 Mn |
| Sep 30, 2018 | 4.50 Mn |
| Jun 30, 2018 | 10.87 Mn |
| Mar 31, 2018 | 8.22 Mn |
| Dec 31, 2017 | 2.44 Mn |
| Sep 30, 2017 | 698,902.00 |
| Jun 30, 2017 | 1.32 Mn |
| Mar 31, 2017 | 493,870.00 |